当前位置:首页 - 行情中心 - 近岸蛋白(688137) - 财务分析 - 利润表

近岸蛋白

(688137)

  

流通市值:13.58亿  总市值:29.17亿
流通股本:3267.54万   总股本:7017.54万

利润表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、营业总收入72,094,559.1433,444,619.29127,555,134.7892,079,068.48
  营业收入72,094,559.1433,444,619.29127,555,134.7892,079,068.48
二、营业总成本84,803,092.5741,376,150.08166,495,773.97115,556,413.23
  营业成本25,614,277.912,622,698.2847,989,594.7832,652,717.32
  税金及附加535,546.95295,607.191,451,274.681,212,448.88
  销售费用26,113,512.5912,430,941.9951,933,890.0734,818,725.83
  管理费用21,934,529.4110,660,333.2249,153,756.3237,305,567.98
  研发费用26,101,953.2913,318,794.249,922,930.6233,757,447.63
  财务费用-15,496,727.57-7,952,224.8-33,955,672.5-24,190,494.41
  其中:利息费用1,387,729.81760,243.023,587,125.112,782,177.92
  其中:利息收入17,216,346.278,820,335.2336,906,796.5327,524,514.45
三、其他经营收益
  加:公允价值变动收益---1,804,926.16-1,804,926.16
  加:投资收益267,479.91267,479.914,569,887.114,569,887.11
  资产处置收益731,409.51-141,603.68-
  资产减值损失(新)-18,127,681.15-8,321,843.97-32,094,508.76-19,097,136.16
  信用减值损失(新)827,598.9357,960.39-2,448,524.63-3,525,505.81
  其他收益455,821.31374,528.2817,497,032.8816,364,793.21
四、营业利润-28,553,904.92-15,553,406.18-53,080,075.07-26,970,232.56
  加:营业外收入17,046.8511,480.248,271.6348,257.1
  减:营业外支出381,037.07279,966.861,186,467.8676,107.9
五、利润总额-28,917,895.14-15,821,892.84-54,218,271.24-27,598,083.36
  减:所得税费用-4,694,324.32-4,013,489.43198,010.86-9,339,548.27
六、净利润-24,223,570.82-11,808,403.41-54,416,282.1-18,258,535.09
(一)按经营持续性分类
  持续经营净利润-24,223,570.82-11,808,403.41-54,416,282.1-18,258,535.09
(二)按所有权归属分类
  归属于母公司股东的净利润-24,223,570.82-11,808,403.41-54,416,282.1-18,258,535.09
  扣除非经常损益后的净利润-26,684,693.64-12,404,641.19-71,748,588.94-32,707,388.88
七、每股收益
  (一)基本每股收益-0.35-0.17-0.78-0.26
  (二)稀释每股收益-0.35-0.17-0.78-0.26
八、其他综合收益12,987.8221,986.91-23,123.46,228.41
  归属于母公司股东的其他综合收益12,987.8221,986.91-23,123.46,228.41
九、综合收益总额-24,210,583-11,786,416.5-54,439,405.5-18,252,306.68
  归属于母公司股东的综合收益总额-24,210,583-11,786,416.5-54,439,405.5-18,252,306.68
公告日期2025-08-282025-04-292025-04-292024-10-30
审计意见(境内)标准无保留意见
TOP↑